恩度联合胸腹腔内化疗治疗恶性胸腹水的临床观察  

Clinical observation of endostar combined with thoracic,abdominal cavity chemotherapy in treatment of malignant hydrothorax and ascites

作　　者：吴书庆[1] 

机构地区：[1]江苏省丹阳市人民医院肿瘤科,江苏丹阳212300

出　　处：《中国肿瘤临床与康复》2013年第1期56-58,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨恩度(重组人血管内皮抑制素)联合胸、腹腔内化疗治疗恶性胸、腹水的临床疗效及不良反应。方法选取2008年1月至2011年1月间住院治疗的76例恶性胸、腹水患者,随机分为观察组(恩度联合胸、腹腔内化疗治疗)和对照组(胸、腹腔内化疗治疗),每组各38例,观察比较两组治疗效果。结果观察组总有效率为78.9%,对照组总有效率为57.9%,两组疗效比较,差异有统计学意义(P<0.05)。结论恩度联合胸、腹腔内化疗治疗恶性胸、腹水的临床疗效良好,明显优于常规化疗治疗。Objective To evaluate the efficacy and adverse reaction of Endostar combined with thoracic,abdominal cavity chemotherapy in treatment of malignant hydrothorax and ascites.Methods From January 2008 to January 2011,76 cases of patients with malignant hydrothorax and ascites were randomly divided into the observation group（38 cases,endostar combined with thoracic,intraperitoneal chemotherapy treatment）and the control group（38 cases,thoracic,abdominal cavity chemotherapy treatment）,curative effect were compared between the two groups.Results In the observation group,the total effective rate was 78.9%;the control group the total efficiency was 57.9%,comparison of the two groups has significant difference（P0.05）,with statistical significance.Conclusions Endostar combined with thoracic,abdominal cavity chemotherapy in treatment of malignant hydrothorax and ascites,clinical curative effect is good,and is obviously superior to conventional chemotherapy.

关 键 词：恩度 药物疗法 胸水 腹水 不良反应 

分 类 号：R730.5[医药卫生—肿瘤]